On-Demand Webinar: Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows
Overview
Within the fast-developing field of antibody drug discovery, the ability to effectively screen and characterize antibodies, and antibody drug conjugates (ADCs), is vital for developing effective therapeutics, including anti-HER2 cancer therapies.
From the research laboratory bench to the clinic, scientists increasingly seek comprehensive workflows, for the high-throughput screening, and detailed analysis of antibody binding and functionality.
This webinar shares details of how cross platform integration, can streamline and enhance the antibody profiling process. Highlighted techniques include High-Throughput Screening (HTS) Cytometry, automated cell picking and Label-Free Analysis.
The webinar also includes:
- Details of live cell binding assays, antibody internalization and the assessment of antibody-dependent cellular cytotoxicity (ADCC).
- Information on the advantages of cross platform integration, including rapid and robust antibody characterization, which accelerate the drug discovery pipeline.
- Case studies on Trastuzumab and ADCs such as Kadcyla® and Enhertu®.
Explanations of how Label-Free Analysis provides a deeper understanding of antibody-antigen interactions.
Webinar Speaker
Daryl Cole Ph.D.
Scientist, Sartorius
Daryl Cole earned a Ph.D. in Molecular Oncology from King’s College London in 2008, and joined Sartorius in 2021 as a Scientist in the Bio Applications Team, working on iQue®, Incucyte®, Octet® and CellCelector applications development.
He has over 15 years of experience in a range of scientific fields, from cancer research to organoid and stem cell development.
